This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients(n=689) who underwent successful stenting were randomly assigned to receive cilostazol(group 1, n=344, 612 les...This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients(n=689) who underwent successful stenting were randomly assigned to receive cilostazol(group 1, n=344, 612 lesions) or clopidogrel(group 2, n=345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days(2.6%in group 1 vs 2.0%in group 2, p=0.61) and side effects that required cessation of study drug(0.6%each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.展开更多
Despite concerns regarding the long-term safety of drug-eluting stent(DES) implantation because of late-onset stent thrombosis, the actual incidence of stent thrombosis after 1 year is unknown. We investigated the inc...Despite concerns regarding the long-term safety of drug-eluting stent(DES) implantation because of late-onset stent thrombosis, the actual incidence of stent thrombosis after 1 year is unknown. We investigated the incidence, risk factors, and association of antiplatelet therapy interruption for the development of stent thrombosis after DES implantation during long-term follow-up. A total of 1,911 consecutive patients with DES implantation were enrolled(sirolimus-eluting stents in 1,545 patients, 2,045 lesions; paclitaxel-eluting stents in 366 patients, 563 lesions). During long-term follow-up(median 19.4 months, interquartile range 15.3 to 24.3), 15 patients(0.8%, 95%confidence interval 0.5%to 1.3%) developed stent thrombosis within 6 hours to 20.4 months. Eleven patients(0.6%, 95%confidence interval 0.3%to 1.0%) had late thrombosis(median 6.1 months). The incidence of stent thrombosis was 3.3%(4 of 121 patients) in patients with complete interruption of antiplatelet therapy(vs 0.6%in those without, p=0.004) and 7.8%(5 of 64 patients) with premature interruption of aspirin or clopidogrel, or both(vs 0.5%in those without, p< 0.001). Independent predictors of stent thrombosis were premature antiplatelet therapy interruption, primary stenting in acute myocardial infarction, and total stent length. Stent thrombosis also developed while patients were on dual antiplatelet therapy(all patients with acute/subacute stent thrombosis and 36%of those with late stent thrombosis; 47%of total with stent thrombosis). In conclusion, stent thrombosis occurred in 0.8%after DES implantation during long-term follow-up. The incidence of late stent thrombosis was 0.6%, similar to that for bare metal stents. The predictors of stent thrombosis were premature antiplatelet therapy interruption, primary stenting in acute myocardial infarction, and total stent length.展开更多
To report a case of sparganosis in the muscle layer of the eyelid. Observation al case report. A 67 year old man with migratory painful swelling on the eyeli d that was unresponsive to medications was evaluated and tr...To report a case of sparganosis in the muscle layer of the eyelid. Observation al case report. A 67 year old man with migratory painful swelling on the eyeli d that was unresponsive to medications was evaluated and treated surgically. Com puted tomography showed a 1.5×1.5 cm sized, thick walled lesion and ultrasound biomicroscopy showed hypoechoic tubular and cystic lesions. During surgery, a w hite, thread like plerocercoid, 7 cm in length was detected in the orbicularis muscle of the lower eyelid. Histopathologic examination demonstrated the charact eristic feature of the sparganum larva and foreign body granulomatous reaction. Serodiagnosis by enzyme linked immunosorbent assay was positive. Three months p ostoperatively, the lesion resolved completely. Although rare, sparganosis shoul d be suspected in a moving eyelid mass unresponsive to the medical treatment.展开更多
文摘This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients(n=689) who underwent successful stenting were randomly assigned to receive cilostazol(group 1, n=344, 612 lesions) or clopidogrel(group 2, n=345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days(2.6%in group 1 vs 2.0%in group 2, p=0.61) and side effects that required cessation of study drug(0.6%each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.
文摘Despite concerns regarding the long-term safety of drug-eluting stent(DES) implantation because of late-onset stent thrombosis, the actual incidence of stent thrombosis after 1 year is unknown. We investigated the incidence, risk factors, and association of antiplatelet therapy interruption for the development of stent thrombosis after DES implantation during long-term follow-up. A total of 1,911 consecutive patients with DES implantation were enrolled(sirolimus-eluting stents in 1,545 patients, 2,045 lesions; paclitaxel-eluting stents in 366 patients, 563 lesions). During long-term follow-up(median 19.4 months, interquartile range 15.3 to 24.3), 15 patients(0.8%, 95%confidence interval 0.5%to 1.3%) developed stent thrombosis within 6 hours to 20.4 months. Eleven patients(0.6%, 95%confidence interval 0.3%to 1.0%) had late thrombosis(median 6.1 months). The incidence of stent thrombosis was 3.3%(4 of 121 patients) in patients with complete interruption of antiplatelet therapy(vs 0.6%in those without, p=0.004) and 7.8%(5 of 64 patients) with premature interruption of aspirin or clopidogrel, or both(vs 0.5%in those without, p< 0.001). Independent predictors of stent thrombosis were premature antiplatelet therapy interruption, primary stenting in acute myocardial infarction, and total stent length. Stent thrombosis also developed while patients were on dual antiplatelet therapy(all patients with acute/subacute stent thrombosis and 36%of those with late stent thrombosis; 47%of total with stent thrombosis). In conclusion, stent thrombosis occurred in 0.8%after DES implantation during long-term follow-up. The incidence of late stent thrombosis was 0.6%, similar to that for bare metal stents. The predictors of stent thrombosis were premature antiplatelet therapy interruption, primary stenting in acute myocardial infarction, and total stent length.
文摘To report a case of sparganosis in the muscle layer of the eyelid. Observation al case report. A 67 year old man with migratory painful swelling on the eyeli d that was unresponsive to medications was evaluated and treated surgically. Com puted tomography showed a 1.5×1.5 cm sized, thick walled lesion and ultrasound biomicroscopy showed hypoechoic tubular and cystic lesions. During surgery, a w hite, thread like plerocercoid, 7 cm in length was detected in the orbicularis muscle of the lower eyelid. Histopathologic examination demonstrated the charact eristic feature of the sparganum larva and foreign body granulomatous reaction. Serodiagnosis by enzyme linked immunosorbent assay was positive. Three months p ostoperatively, the lesion resolved completely. Although rare, sparganosis shoul d be suspected in a moving eyelid mass unresponsive to the medical treatment.
